Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to 0.85.

  • Altimmune's Equity Ratio fell 580.76% to 0.85 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.85, marking a year-over-year decrease of 580.76%. This contributed to the annual value of 0.89 for FY2024, which is 378.5% down from last year.
  • Per Altimmune's latest filing, its Equity Ratio stood at 0.85 for Q3 2025, which was down 580.76% from 0.85 recorded in Q2 2025.
  • In the past 5 years, Altimmune's Equity Ratio registered a high of 0.94 during Q2 2021, and its lowest value of 0.85 during Q2 2025.
  • In the last 5 years, Altimmune's Equity Ratio had a median value of 0.9 in 2023 and averaged 0.9.
  • In the last 5 years, Altimmune's Equity Ratio soared by 2093.92% in 2021 and then plummeted by 580.76% in 2025.
  • Quarter analysis of 5 years shows Altimmune's Equity Ratio stood at 0.91 in 2021, then dropped by 1.58% to 0.9 in 2022, then grew by 2.91% to 0.92 in 2023, then decreased by 3.78% to 0.89 in 2024, then decreased by 4.17% to 0.85 in 2025.
  • Its Equity Ratio was 0.85 in Q3 2025, compared to 0.85 in Q2 2025 and 0.9 in Q1 2025.